I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $497.96M

Company

Location

Date

Amt. (M)

Details

Achillion Pharmaceuticals Inc.

New Haven, Conn.

11/22

$6.5

Achillion raised $6.5M in venture funding supplied by Schroder Ventures, Atlas Venture and Advent International, as well as Connecticut Innovations Inc.

Adherex Technologies Inc.

Ottawa, Ontario

11/7

C$10.3 US$6.73

Adherex completed a $6.73M financing, its final round before going public with an IPO targeted for February

Artecel Sciences Inc.

Durham, N.C.

11/28

$4

Artecel completed a $4M first-round financing, led by Eno River Capital LLC; other investors included TriState Investment Group IV LLC, BioWorld Venture Capital Corp., Fujisawa Investments for Entrepreneurship LP, and several individual investors

Arpida

Munchenstein, Switzerland

11/8**

CHF40 US$22.6

Apida raised US$22.6M in its second round of funding

Arradial Inc.

Boston

11/17

$3

Arradial completed an initial venture capital financing of $3M; the round was led by Oxford Bioscience Partners and included an investment from Boston University's Community Technology Fund

Big Bear Bio Inc.

Austin, Texas

11/22

$5.1

Big Bear Bio raised $5.1M in its first round of financing; the round was led by Life Science Venture Fund

CellFactors plc

London

11/29**

#1.6 US$2.3

CellFactors raised US$2.3M in a seed funding round

Coley Pharmaceutical Inc.

Wellesley, Mass.

11/1

$60

Coley completed a $60M international private financing led by DWS Investment GmbH; investors included DVG, Commerzbank Private Equity, Robertson Stephens' Bayview 2000, Global Life Science Partners, Techno Venture Management, Quiagen N.V., Alpinvest Holding N.V. and Alafi Capital

Cytokinetics Inc.

South San Francisco

11/22

$55

Cytokinetics raised $55M in its third round of private financing; investors included Mayfield Fund, Vulcan Ventures Inc., Sevin Rosen Funds, CSFB Private Equity, Alta Partners and Lombard Odier & Cie

Cytovax Biotechnologies Inc.

Edmonton, Alberta

11/1

C$7.9 US$5.1

Cytovax sold more than 1.9M special warrants in September and October; Acumen Capital Finance Partners Ltd. and Goepel McDermid Inc. acted as agents

Cytran Inc.

Kirkland, Wash.

11/10

$17

Cytran closed a $17M private placement of convertible debentures; the round included lead investments by Alza Corp. and Stephens Group Inc.

Epigenomics AG

Berlin

11/14

EUR28 US$24

Epigenomics completed a second-round financing totaling EUR28M; investors included Deutsch Venture Capital Gessellschaft and a number of new investors from the international investment community, including MPM Asset Management, 3i and Abingworth Management

Immuno-Designed Molecules SA

Paris

11/20

EUR48.9 US$41.6

Immuno-Designed Molecules completed its third round of financing from private investors; the round was led by Fortis Bank

Islet Technology Inc.

St. Paul, Minn.

11/30

$1.75

Islet raised $1.75M in a private placement equity financing; Peterson Brothers Securities Co. assisted with a portion of the financing

Kreatech Biotechnology BV

Amsterdam

11/9

US$3.41

Kreatech raised US$3.41 in a private placement of stock with Alafi Capital and Life Sciences Partners; Bank Ten Cate & Cie NV led the round

Locus Discovery Inc.

Princeton, N.J.

11/28

$42.75

Locus raised $42.75M in its second round of private equity financing through the issuance of preferred stock; the round was led by Cooper Hill Partners and included Origin Capital, Amerindo Investment Advisers, Invesco Global Health Sciences Fund, Prism Venture Partners, Dresdner Klienwort Benson, Delphi Ventures, Johnson & Johnson Development Corp., Tredegar Investments and ReqMed Co., among others

Microbia Inc.

Cambridge, Mass.

11/2

$23

Microbia raised $23M in a second round of private equity financing; investors included BancBoston Ventures, Essex Investment Management Co., Venrock Associates, Polaris Venture Partners, Aberdare Ventures and numerous others

MelTec GmbH

Magdeburg, Germany

11/20

DM38 US$16.5

MelTec completed its initial round of financing led by Volksbank Magdeburg and the community task program of Saxony-Anhalt

MMI Group plc

Cambridge, England

11/8**

#3.5 US$5

MMI raised US$5M to fund its international expansion

Novelos Therapeutics Inc.

Newton, Mass.

11/15

$3.3

Novelos completed a first round of private equity financing totaling $3.3M; Masthead Venture Partners was the lead institutional investor in this financing.

Noxxon Pharma AG

Berlin

11/15

EUR20 US$17

Noxxon raised over EUR20M in a second-round private equity financing; Merlin Biosciences led the financing, which included investors Westdeutsche Landesbank Girozentrale and Hannover Finanz GmbH

Onyvax Ltd.

London

11/16

EUR17.5 US$14.9

Onyvax raised US$14.9M through a private placement with MB Venture Capital Fund I, Merlin Biosciences Fund, 3i S.R. One Ltd. and Alta Berkeley Venture Partners

Rademacher Group Ltd.

Oxford, UK

11/20

#8.6 US$12.26

Rademacher raised US$12.26M in a funding round led by Johnson & Johnson Development Corp.; other investors were Northern Ventures, Apax and Advent Venture Partners

Scynexis Chemistry & Automation Inc.

Research Triangle Park, N.C.

11/8

$15

The new company created by the spin-off of an Aventis CropScience research team received $15M in funding from a syndicate of venture capitalists and banks

Vela Pharmaceuticals

Princeton, N.J.

11/1

$16.3

Vela raised $16.3M in a private equity financing led by New Enterprise Associates and Venrock Associates, and including Johnston Associates Inc. and MBF Capital Corp.

ViaCell Inc.

Boston

11/15

$48

ViaCell raised $48M in mezzanine financing; investors included Deutsche Bank, Nomura International, the Stephens Group, Sofinov Societe Financiere D'Innovation Inc., United Offshore Bank Venture Technology Investments Ltd. and Singapore's economic development board, as well as MPM Capital, Zero Stage Capital, Tullis Dickerson and Aurora Assets LLP

Wilex Biotechnology GmbH

Munich, Germany

11/13

EUR30 US$25.86

Wilex closed its third round of financing, raising US$25.86M; investors included Apax Partners and Co., Earlybird Venture Capital, TVM Techno Venture Management GmbH; Merlin BioSciences Ltd., Julius Baer Kapitalanlage AG, Bank Vontobel and BioConnect

Notes:

**Denotes the date the item ran in BioWorld International.

II. MILESTONE PAYMENTS AND EQUITY INVESTMENTS FROM EXISTING CORPORATE PARTNERS: $10.5M

Company (Symbol)#

Partner (Symbol; Country)

Amt. (M)

Triggering Event

Details (Date)

Avanir Pharmaceuticals Inc. (AMEX:AVN)

SmithKline Beecham Consumer Healthcare (NYSE:SBH)

$5

Milestone payment

Avanir received a milestone payment for the initiation of the distribution of Abreva at the wholesale level (11/30)

Exelixis Inc. (EXEL)

Bayer AG (Germany)

ND

Milestone payment

Genoptera LLC, a joint venture between Bayer and Exelixis, delivered several novel insecticide targets for assay development and screening to Bayer, triggering undisclosed milestone payments to Exelixis (11/15)

Neurobiological Technologies Inc. (NTII)

Merz & Co.

$2.5

Up-front payment

Neurobiological Technologies received a $2.5M payment from Merz relating to Memantine; the payment is triggered by monies received by Merz pursuant to agreements between Merz and Forest Laboratories Inc. and A/S Lundbeck (11/1)

Response Genetics Inc.*

Dianon Systems Inc.*

$1

Equity investment

Dianon made an equity investment in Response in connection with a sales and distribution agreement for the Danenberg Tumor Profile chemotherapy guidance system (11/16)

Structural Bioinformatics*

IBM

ND

Equity investment

IBM made an unspecified equity investment in Structural Bioinformatics; the companies are collaborating to make protein structural databases more readily available to researchers on a subscription basis via the Internet (11/29)

Targeted Genetics Corp. (TGEN)

Celltech Group plc (UK; LSE:CCH; NYSE:CLL)

$2

Milestone payment

Targeted Genetics received a $2M milestone payment for starting a Phase II trial of tgAAV-CF for cystic fibrosis (11/17)

Versicor Inc. (VERS)

Novartis Pharma AG (Switzerland)

ND

Milestone payment

Versicor achieved a second milestone in its three-year collaboration with Novartis, and will receive a second milestone payment for an assay, which has been implemented in Novartis' high-throughput screening lab to identify new anti-infective drugs (11/15)

Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

*Denotes privately held company. ND = not disclosed